Skip to main content

Day: August 24, 2022

Lerøy Seafood Group ASA: Q2 2022 Results

HIGH PRICES GIVES RECORD HIGH QUARTERLY REVENUE Operating profit for Q2 2022 excluding settlement costs and before fair value adjustment is NOK 923 million, up 58% on the same period of 2021. Strong demand for seafood, including a substantial increase in prices realised for the Group’s main products, is the key factor in the year-on-year earnings improvement. The Farming segment delivered improved results in the quarter. Salmon prices were high again in the second quarter, based on continued high demand and low supply. The harvest volume was slightly lower than in the same period of 2021 but will increase in the second half of the year. Inflationary pressure in the economy and the low harvest volume are affecting cost developments. The total salmon and trout harvest volume for full-year 2022 is estimated at 203,000 GWT (including Lerøy’s...

Continue reading

CORRECTION — Fanhua Reports Second Quarter and First Half 2022 Unaudited Financial Results

GUANGZHOU, China, Aug. 24, 2022 (GLOBE NEWSWIRE) — Fanhua Inc. (Nasdaq: FANH) (the “Company” or “Fanhua”), a leading independent financial services provider in China, today announced a correction of a prior press release, “Fanhua Reports Second Quarter and First Half 2022 Unaudited Financial Results” issued at 5PM on August 23, 2022. The cash, cash equivalents and restricted cash at beginning of period for the six months ended June 20, 2021 in the unaudited condensed consolidated statement of cash flow should read “350,098” instead of “1,219,436” and the cash, cash equivalents and restricted cash at end of period for the six months ended June 20, 2021 in the unaudited condensed consolidated statement of cash flow should read “429,330” instead of “1,298,668” as originally issued inadvertently. The complete, correct release follows. Fanhua...

Continue reading

Company Announcement 10/2022

August 24, 2022 NORDIC SHIPHOLDING A/SCompany Announcement: 10/2022 Published via NASDAQ OMX on August 24, 2022H1 Result 2022SummaryThe comparison figures for the period ended 30 June 2022 are stated in parenthesis.The operating performance of the Group for H1 2022 was impacted by the sale of the remaining three vessels. The last vessel, Nordic Amy, was delivered to her new owner on 1 April 2022. The Group generated a profit after tax of USD 3.6 million (including write-off of certain loan interest of USD 3.9 million on the vessels) in H1 2022 compared to a loss after tax of USD 6.0 million for the same period last year. TCE revenue in Q2 2022 was recognised due to IFRS 15 reversals and revision of previous periods’ pool distributions by pool managers. Despite the improvement in average TCE rates in Q1 2022, the loss of earnings...

Continue reading

Allied Copper provides Update on Stateline Option Agreement

Vancouver, British Columbia, Canada, Aug. 23, 2022 (GLOBE NEWSWIRE) — Allied Copper Corp. (TSX-V: CPR, OTCQB: CPRRF) (the “Company” or “Allied Copper”), previously announced on February 10, 2022 that the Company signed an option agreement (the “Agreement”) dated February 9, 2022 for the sole and exclusive right to acquire a 100% undivided legal and beneficial interest (subject to a 2% net smelter royalty) for the Stateline Property, CO/UT USA from Cloudbreak Discovery Plc (“Cloudbreak” (LSE: CDL), Cloudbreak Discovery Canada Ltd., Tarsis Resources US Inc. and Alianza Minerals Ltd. (“Alianza”) (TSX-V: ANZ) (collectively, the “Alliance”). The Company and the Alliance have now successfully executed an amending agreement dated August 5, 2022 with effect as of February 9, 2022, amending the Agreement to delay any security issuance by...

Continue reading

Bright Minds Announces Pricing of Overnight Marketed Offering of Units

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British Columbia, Aug. 23, 2022 (GLOBE NEWSWIRE) — Bright Minds Biosciences Inc. (“Bright Minds” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy and pain, is pleased to announce the pricing of its previously announced overnight marketed offering of an aggregate of 2,858,000 units of the Company (the “Units”) at a price of $1.40 per Unit, for aggregate gross proceeds of $4,001,200 (the “Offering”). Each Unit is comprised of one common share in the capital of the Company (a “Share”) and one common share purchase warrant (a “Warrant”). Each Warrant will entitle the holder thereof to purchase one Share at an exercise...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.